TABLE 1.
Overview of a 29-factor model.
| Factor number | Label | Dimension | Size | Highest loading |
|---|---|---|---|---|
| F1 | COVID-19 outbreak 2019/2020 | I | 57 | 1.06 |
| F2 | SARS outbreak 2002 | I | 31 | 1.07 |
| F3 | MERS outbreak 2012 | I | 28 | 1.08 |
| F4 | RNA transcription | II | 15 | 1.12 |
| F5 | Replication | II | 11 | 1.33 |
| F6 | Outbreaks of other human coronaviruses | I | 14 | 1.17 |
| F7 | Characterization of viruses in bats | I | 12 | 1.11 |
| F8 | Internalization of murine coronaviruses | II | 13 | 1.06 |
| F9 | SARS vaccine development | III | 13 | 1.03 |
| F10 | Gene expression/translation | II | 12 | 1.1 |
| F11 | Release | II | 12 | 1.15 |
| F12 | Feline coronaviruses | IV | 8 | 1.01 |
| F13 | Internalization | II | 8 | 1.08 |
| F14 | Porcine delta coronavirus and epidemic diarrhea virus | IV | 7 | 1.05 |
| F15 | 3CL protease as target | III | 6 | 1.07 |
| F16 | Animal models | III | 6 | 0.75 |
| F17 | MERS spike protein as target | III | 2 | 0.78 |
| F18 | Avian | IV | 6 | 1.04 |
| F19 | Porcine TGEV and PRCV | IV | 7 | 1.03 |
| F20 | Early findings about coronavirus | II | 5 | 0.75 |
| F21 | SARS nucleocapsid protein | II | 5 | 0.98 |
| F22 | UD (clinical intensive care) | I | 0 | — |
| F23 | ACE2 | III | 4 | 0.75 |
| F24 | Bovine coronaviruses | IV | 5 | 0.94 |
| F25 | Canine coronaviruses | IV | 4 | 1.05 |
| F26 | Model forecasts of epidemics | I | 1 | 0.8 |
| F27 | UD (clinical treatment regimes) | I | 2 | 0.66 |
| F28 | UD (papain-like protease) | II | 3 | 0.63 |
| F29 | CNS involvement of murine coronavirus | II | 2 | 1.01 |